Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Serum Institute of India (India) · University of Oxford · +6 more institutions
Abstract
No abstract available for this paper.
Citation impact
- FWCI
- 54.00
- Percentile
- 100%
- References
- 6
Authors
33- MSMehreen S. DatooCorresponding
Serum Institute of India (India), University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute, Novavax (Sweden), Institut de Recherche en Sciences de la Santé
- HMHamtandi Magloire Natama
Serum Institute of India (India), University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute, Novavax (Sweden), Institut de Recherche en Sciences de la Santé
- ASAthanase Somé
Serum Institute of India (India), University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute, Novavax (Sweden), Institut de Recherche en Sciences de la Santé
- DBDuncan Bellamy
Serum Institute of India (India), University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute, Novavax (Sweden), Institut de Recherche en Sciences de la Santé
- OTOusmane Traoré
Serum Institute of India (India), University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute, Novavax (Sweden), Institut de Recherche en Sciences de la Santé
Topics & keywords
- Medicine
- Malaria
- Malaria vaccine
- Vaccination
- Population
- Immunogenicity
- Clinical trial
- Randomized controlled trial
- Good health and well-being